Recent Advances in Ophthalmology 2026: MCQs on What's New
“Recent advances” is not a list of buzzwords to memorise once. For an examination answer, an update needs four labels: the entity, its mechanism, the evidence source, and the jurisdiction/date for any regulatory statement. A promising trial, a regulatory decision, local availability and routine practice are different claims.
Use this as closed-book retrieval practice. Answer five questions at a time, then write the source you would open to verify each missed update. The examples below are deliberately anchored to published reports and durable concepts; they do not claim a current 2026 approval, indication, dose, availability or guideline recommendation. This is postgraduate exam education, not patient-care advice.
Trial and regulatory-literacy MCQs
1. What is the first question to ask when a stem says a treatment is “approved”?
Answer: By which regulator and in which jurisdiction? Regulatory status is not global. A correct viva answer names the regulator, the country or region, the labelled indication and the date checked; “approved” without those qualifiers is incomplete.1
2. A device “clearance” and a drug “approval” should be treated as:
Answer: Different regulatory concepts. The US FDA’s drug databases and its 510(k) device database are separate verification routes. Do not use the word clearance as a generic substitute for a drug approval, or infer one from the other.12
3. Where should you first check a trial’s registered primary outcome and recruitment status?
Answer: The trial registry record. A registry is a stronger first source for design, prespecified outcome and listed status than a social-media post or a news headline. It does not by itself replace reading the final paper.3
4. What does a non-inferiority trial require for interpretation?
Answer: Its prespecified non-inferiority margin. “Non-inferior” does not automatically mean superior, identical, cheaper or preferred. The comparator, margin, analysis set and endpoint all matter.4
5. Why is a surrogate endpoint not automatically a patient-important outcome?
Answer: It measures a proxy, not necessarily how a patient functions or feels. A biological or anatomical change may be meaningful, but an exam answer should name the endpoint instead of silently equating it with every clinical benefit.
6. The primary endpoint of a trial is best described as:
Answer: The outcome specified as the main test of the study question. A secondary outcome can be useful, but it should not be presented as though it were the primary result. Check the protocol or registry when a report’s wording is unclear.3
7. What is a common limitation of a conference abstract compared with a full report?
Answer: It usually provides less detail on methods, denominators, harms and follow-up. An abstract can flag an update worth checking, but it is a weak foundation for a detailed treatment or regulatory statement.
8. What does “real-world evidence” usually describe?
Answer: Evidence from routine-practice or observational data rather than a randomised trial alone. It can be valuable, but confounding, selection and missing-data risks differ from those in a randomised study. Name the design before claiming what it proves.
Retina and drug-development MCQs
9. Faricimab was designed to target which two pathways?
Answer: Angiopoietin-2 and VEGF-A. The TENAYA and LUCERNE report is a mechanism and trial-design source. A published mechanism does not establish a current indication in every territory; verify the live label separately.4
10. In a dosing-interval question, what must be separated from a molecule’s mechanism?
Answer: The regimen actually studied or labelled. “Longer interval” is not a universal property of a drug class. State which regimen, population and source the question is referring to rather than turning one study schedule into a blanket rule.4
11. Pegcetacoplan acts at which broad immune pathway component?
Answer: Complement component 3 (C3). The OAKS and DERBY publication is a source for trial terminology around C3 inhibition and geographic-atrophy research. It should not be used as a substitute for a current local product label.5
12. A phase-3 trial report can establish which of the following most directly?
Answer: Results for the population, comparator and endpoints studied. It cannot by itself establish that every regulator has authorised a product, that every patient is eligible, or that it is available in a given health system.
13. What is the safest way to answer a question about a newly reported retinal therapy?
Answer: Give mechanism, study type and population first; then verify live regulatory status. This structure earns more than a bare brand name because it distinguishes evidence from an operational claim.
14. A biosimilar’s name alone tells you what about interchangeability?
Answer: Not enough. Biosimilar and interchangeability determinations are jurisdiction-specific regulatory matters. Check the appropriate regulator’s current product-information source rather than assuming a class-wide status.6
15. What is an important adverse-event reading rule in a recent-advances stem?
Answer: Compare the event with the study population, exposure and comparator. A raw event count without denominators or follow-up cannot establish comparative risk. Read the safety table and the study design together.
16. Which statement best separates a trial publication from a label?
Answer: A publication reports a study; a label describes an authorised use in a named jurisdiction. They may overlap, but neither should be casually substituted for the other.1
Gene therapy, imaging and AI MCQs
17. In a gene-therapy question, which four fields should be named before any current-status claim?
Answer: Disease/genotype, vector or payload, route of administration, and eligibility context. This prevents an answer from implying that a genetic therapy applies to all inherited retinal disease.7
18. Voretigene neparvovec’s pivotal report is an example of what evidence category?
Answer: A published interventional trial in a defined inherited-retinal-disease population. It is useful for learning how to frame gene-therapy evidence, not for making universal claims about current access or eligibility.7
19. Why is genotype essential in many inherited-retinal-disease therapy questions?
Answer: A molecular therapy may be designed for a specific disease mechanism or genetic context. “Inherited retinal dystrophy” is a broad umbrella and is usually too nonspecific for a single-best-answer stem.
20. OCT is primarily what kind of imaging?
Answer: Cross-sectional structural imaging. It depicts retinal architecture and compartments. It does not show dye leakage behaviour, so do not choose OCT when the stem asks about progressive fluorescein leakage.8
21. OCT angiography (OCT-A) uses what principle?
Answer: Flow contrast. OCT-A derives vascular information from motion/flow-related signal variation; it is not conventional fluorescein angiography and does not supply every dynamic dye-angiography feature.8
22. In an AI-paper MCQ, what does external validation mean?
Answer: Testing the model on data outside the original development dataset. A high internal test score is not the same as demonstrating transportability to another device, site, population or workflow.3
23. Why should an AI diagnostic model’s reference standard be stated?
Answer: Model performance is interpretable only against the standard used to label the data. A model compared with expert grading, a consensus panel or another test may answer different questions.3
24. What is dataset shift?
Answer: A meaningful difference between development data and new-use data. It may arise from a different camera, prevalence, referral pathway, population or annotation method. A “validated AI” claim needs context about where and how it was tested.3
Glaucoma, cornea and procedural-innovation MCQs
25. The LiGHT trial is commonly used as an example of what comparison?
Answer: A trial comparing an initial selective laser trabeculoplasty pathway with an initial eye-drop pathway in a defined glaucoma/ocular-hypertension setting. It does not remove the need to check current guideline wording and local practice.9
26. What does SLT stand for?
Answer: Selective laser trabeculoplasty. “Selective” refers to its laser-tissue interaction concept; the acronym alone does not specify whether it is appropriate for a particular individual.
27. MIGS is best understood as:
Answer: A family of minimally invasive glaucoma surgery approaches, not one procedure or one mechanism. In a viva, identify the outflow pathway and device/procedure rather than saying “MIGS” as though it were a single operation.
28. What evidence question should follow a new glaucoma-device headline?
Answer: Compared with what, in which glaucoma type, over what follow-up, and with which safety outcomes? That sequence prevents a device announcement from being mistaken for durable comparative effectiveness.
29. In corneal cross-linking, what is the core biological aim in examination language?
Answer: To increase corneal stromal biomechanical stiffness through collagen cross-linking. A patient-specific indication or protocol is outside this MCQ; protocols and eligibility require current local and regulatory checks.
30. Why should a refractive-laser acronym not be treated as an outcome claim?
Answer: The acronym identifies a technique, not a guaranteed visual result, safety profile or eligibility threshold. An exam answer should explain the tissue plane or optical principle before making any comparative statement.
31. A new intraocular-lens technology is most safely introduced in a viva by stating:
Answer: Its optical principle, intended trade-off and evidence source. Avoid presenting a design feature as a promise of spectacle independence, dysphotopsia avoidance or universal superiority.
32. What does a learning curve threaten in an early procedural study?
Answer: Transferability of results. Outcomes can depend on operator experience, patient selection and centre volume. A small early series cannot automatically establish performance across settings.
The update-check method MCQs
33. What is the strongest source hierarchy for a mutable drug-approval claim?
Answer: The current named regulator’s official product/approval record. A journal article or company release may provide context, but use the regulator for a present-tense approval assertion.1
34. What is the strongest first source for whether a registered trial is recruiting, completed or withdrawn?
Answer: Its current registry record. Read the “last update” date and identify the registry number. A dated paper cannot show a trial status change that happened after publication.3
35. What should be recorded beside every “recent advance” in a revision notebook?
Answer: Entity, mechanism, evidence type, jurisdiction, source URL and checked-on date. This turns fragile recall into an auditable answer and makes final pre-exam updating much faster.
36. Why can a 2024 or 2025 source still be useful in a 2026 article?
Answer: It can support a stable mechanism or published trial result. The error is using it to assert a changing 2026 approval, label, availability or guideline recommendation without a live check.
37. What does it mean if a trial met a primary endpoint?
Answer: It met the study’s prespecified main outcome under its reported analysis. It does not automatically establish clinical superiority, broad eligibility, regulatory authorisation or cost-effectiveness.
38. What is the right response when an MCQ’s answer depends on a current label you cannot verify?
Answer: State the mechanism and published evidence, then say that the current label must be checked. Withholding an unverified present-tense claim is more accurate than guessing a dose, indication or territory.
39. Why is a jurisdiction line especially important for AI/software and devices?
Answer: Regulatory categories and authorisations can differ between markets. “Available abroad” does not prove clearance, approval, access or intended use in the reader’s setting.2
40. What is the most defensible final sentence for a “what’s new” answer?
Answer: “This is the published mechanism and evidence; I would verify the current regulator, label, jurisdiction and guideline before applying a present-tense claim.” It signals source discipline without pretending that all recent evidence is already routine practice.
Build a recent-advances error log
For each wrong answer, write one line in this format:
| Field | Example prompt |
|---|---|
| Mechanism | “What pathway or optical principle is being changed?” |
| Evidence | “Registry, phase-3 report, observational study or guideline?” |
| Boundary | “What did the study not establish?” |
| Freshness | “Which regulator/jurisdiction and what checked-on date?” |
For mixed retrieval practice, use the high-yield MCQ set. The resources hub is a verified route to broader study material, and the ophthalmology glossary can resolve a term before you return to a paper. For topic-organised current product information, inspect the Recent Advances in Ophthalmology page; this article does not infer its current contents, updates or access terms.
Sources and scope
These questions are original postgraduate examination-revision prompts. All linked endpoints were checked on 18 August 2026. Reopen the individual regulator, label, registry and guideline immediately before publication or when a question asks for a present-tense operational claim.
Footnotes
-
US Food and Drug Administration. Drug approvals and databases. Live-checked 18 August 2026. ↩ ↩2 ↩3 ↩4
-
US Food and Drug Administration. 510(k) Premarket Notification database. Live-checked 18 August 2026. ↩ ↩2
-
Liu X, Rivera SC, Moher D, et al. Reporting guidelines for clinical-trial reports for interventions involving artificial intelligence: the CONSORT-AI extension. Nature Medicine. 2020; and ClinicalTrials.gov registry gateway. Live-checked 18 August 2026. ↩ ↩2 ↩3 ↩4 ↩5 ↩6
-
Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE). Lancet. 2022. ↩ ↩2 ↩3
-
Heier JS, Lad EM, Holz FG, et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY). Lancet. 2023. ↩
-
US Food and Drug Administration. Biosimilar product information. Live-checked 18 August 2026. ↩
-
Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec in RPE65-mediated inherited retinal dystrophy. Lancet. 2017. ↩ ↩2
-
American Academy of Ophthalmology EyeWiki. Optical Coherence Tomography. Live-checked 18 August 2026. ↩ ↩2
-
Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for the first-line treatment of ocular hypertension and glaucoma (LiGHT). Lancet. 2019. ↩
Ready to apply what you learned?
Practice 10,000+ MCQs with detailed explanations and track your progress.
Start Free Practice